Olanzapine Cipla (previously Olanzapine Neopharma)

Nchi: Umoja wa Ulaya

Lugha: Kiingereza

Chanzo: EMA (European Medicines Agency)

Nunua Sasa

Taarifa za kipeperushi Taarifa za kipeperushi (PIL)
24-07-2014
Tabia za bidhaa Tabia za bidhaa (SPC)
24-07-2014
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma (PAR)
24-07-2014

Viambatanisho vya kazi:

olanzapine

Inapatikana kutoka:

Cipla (EU) Limited

ATC kanuni:

N05AH03

INN (Jina la Kimataifa):

olanzapine

Kundi la matibabu:

Psycholeptics

Eneo la matibabu:

Schizophrenia; Bipolar Disorder

Matibabu dalili:

AdultsOlanzapine is indicated for the treatment of schizophrenia.Olanzapine is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response.Olanzapine is indicated for the treatment of moderate to severe manic episode.In patients whose manic episode has responded to olanzapine treatment, olanzapine is indicated for the prevention of recurrence in patients with bipolar disorder.

Bidhaa muhtasari:

Revision: 12

Idhini hali ya:

Withdrawn

Idhini ya tarehe:

2007-11-14

Taarifa za kipeperushi

                                Medicinal product no longer authorised
101
B. PACKAGE LEAFLET
Medicinal product no longer authorised
102
PACKAGE LEAFLET: INFORMATION FOR THE USER
OLANZAPINE CIPLA 2.5 MG COATED TABLETS
OLANZAPINE CIPLA 5 MG COATED TABLETS
OLANZAPINE CIPLA 7.5 MG COATED TABLETS
OLANZAPINE CIPLA 10 MG COATED TABLETS
OLANZAPINE CIPLA 15 MG COATED TABLETS
olanzapine
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet.
What is in this leaflet
1.
What OLANZAPINE CIPLA is and what it is used for
2.
What you need to know before you take OLANZAPINE CIPLA
3.
How to take OLANZAPINE CIPLA
4.
Possible side effects
5.
How to store OLANZAPINE CIPLA
6.
Contents of the pack and other information
1.
WHAT OLANZAPINE CIPLA IS AND WHAT IT IS USED FOR
OLANZAPINE CIPLA belongs to a group of medicines called antipsychotics
and is used to treat the
following conditions:

Schizophrenia, a disease with symptoms such as hearing, seeing or
sensing things which are not
there, mistaken beliefs, unusual suspiciousness, and becoming
withdrawn. People with this
disease may also feel depressed, anxious or tense.

Moderate to severe manic episodes, a condition with symptoms of
excitement or euphoria.
OLANZAPINE CIPLA has been shown to prevent recurrence of these
symptoms in patients with
bipolar disorder whose manic episode has responded to olanzapine
treatment.
2.
WHAT YOU NEED TO KNOW BEFORE YOU TAKE OLANZAPINE CIPLA
_ _
DO NOT TAKE OLANZAPINE CIPLA

iIf you are allergic (hypersensitive) to olanzapine or any of the
other ingredients of this medicine
(listed in section 6). An allergic re
                                
                                Soma hati kamili

Tabia za bidhaa

                                Medicinal product no longer authorised
1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
Medicinal product no longer authorised
2
1.
NAME OF THE MEDICINAL PRODUCT
Olanzapine Cipla 2.5 mg coated tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each coated tablet contains 2.5 mg olanzapine.
Excipient with known effect: Each coated tablet contains 80.7 mg
lactose monohydrate
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Coated tablet
White, round, biconvex, coated tablets with ‘2.5’ debossing on one
side and ‘OLZ’ on the other.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
_Adults _
Olanzapine is indicated for the treatment of schizophrenia.
Olanzapine is effective in maintaining the clinical improvement during
continuation therapy in
patients who have shown an initial treatment response.
Olanzapine is indicated for the treatment of moderate to severe manic
episode.
In patients whose manic episode has responded to olanzapine treatment,
olanzapine is indicated for
the prevention of recurrence in patients with bipolar disorder (see
section 5.1).
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
_Adults _
Schizophrenia: The recommended starting dose for olanzapine is 10
mg/day.
Manic episode: The starting dose is 15 mg as a single daily dose in
monotherapy or 10 mg daily in
combination therapy (see section 5.1).
Preventing recurrence in bipolar disorder: The recommended starting
dose is 10 mg/day. For patients
who have been receiving olanzapine for treatment of manic episode,
continue therapy for preventing
recurrence at the same dose. If a new manic, mixed, or depressive
episode occurs, olanzapine
treatment should be continued (with dose optimisation as needed), with
supplementary therapy to treat
mood symptoms, as clinically indicated.
During treatment for schizophrenia, manic episode and recurrence
prevention in bipolar disorder,
daily dosage may subsequently be adjusted on the basis of individual
clinical status within the range
5-20 mg/day. An increase to a dose greater than the reco
                                
                                Soma hati kamili

Bidhaa zinazofanana

Viambatanisho vya kazi olanzapine

olanzapine

ATC kanuni N05AH03

N05AH03

Mzalishaji au wazalishaji wadogowadogo Cipla (EU) Limited

Cipla (EU) Limited

INN (Jina la Kimataifa) olanzapine

olanzapine

Nyaraka katika lugha zingine

Taarifa za kipeperushi Taarifa za kipeperushi Kibulgaria 24-07-2014
Tabia za bidhaa Tabia za bidhaa Kibulgaria 24-07-2014
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kibulgaria 24-07-2014
Taarifa za kipeperushi Taarifa za kipeperushi Kihispania 24-07-2014
Tabia za bidhaa Tabia za bidhaa Kihispania 24-07-2014
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kihispania 24-07-2014
Taarifa za kipeperushi Taarifa za kipeperushi Kicheki 24-07-2014
Tabia za bidhaa Tabia za bidhaa Kicheki 24-07-2014
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kicheki 24-07-2014
Taarifa za kipeperushi Taarifa za kipeperushi Kidenmaki 24-07-2014
Tabia za bidhaa Tabia za bidhaa Kidenmaki 24-07-2014
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kidenmaki 24-07-2014
Taarifa za kipeperushi Taarifa za kipeperushi Kijerumani 24-07-2014
Tabia za bidhaa Tabia za bidhaa Kijerumani 24-07-2014
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kijerumani 24-07-2014
Taarifa za kipeperushi Taarifa za kipeperushi Kiestonia 24-07-2014
Tabia za bidhaa Tabia za bidhaa Kiestonia 24-07-2014
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiestonia 24-07-2014
Taarifa za kipeperushi Taarifa za kipeperushi Kigiriki 24-07-2014
Tabia za bidhaa Tabia za bidhaa Kigiriki 24-07-2014
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kigiriki 24-07-2014
Taarifa za kipeperushi Taarifa za kipeperushi Kifaransa 24-07-2014
Tabia za bidhaa Tabia za bidhaa Kifaransa 24-07-2014
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kifaransa 24-07-2014
Taarifa za kipeperushi Taarifa za kipeperushi Kiitaliano 24-07-2014
Tabia za bidhaa Tabia za bidhaa Kiitaliano 24-07-2014
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiitaliano 24-07-2014
Taarifa za kipeperushi Taarifa za kipeperushi Kilatvia 24-07-2014
Tabia za bidhaa Tabia za bidhaa Kilatvia 24-07-2014
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kilatvia 24-07-2014
Taarifa za kipeperushi Taarifa za kipeperushi Kilithuania 24-07-2014
Tabia za bidhaa Tabia za bidhaa Kilithuania 24-07-2014
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kilithuania 24-07-2014
Taarifa za kipeperushi Taarifa za kipeperushi Kihungari 24-07-2014
Tabia za bidhaa Tabia za bidhaa Kihungari 24-07-2014
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kihungari 24-07-2014
Taarifa za kipeperushi Taarifa za kipeperushi Kimalta 24-07-2014
Tabia za bidhaa Tabia za bidhaa Kimalta 24-07-2014
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kimalta 24-07-2014
Taarifa za kipeperushi Taarifa za kipeperushi Kiholanzi 24-07-2014
Tabia za bidhaa Tabia za bidhaa Kiholanzi 24-07-2014
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiholanzi 24-07-2014
Taarifa za kipeperushi Taarifa za kipeperushi Kipolandi 24-07-2014
Tabia za bidhaa Tabia za bidhaa Kipolandi 24-07-2014
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kipolandi 24-07-2014
Taarifa za kipeperushi Taarifa za kipeperushi Kireno 24-07-2014
Tabia za bidhaa Tabia za bidhaa Kireno 24-07-2014
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kireno 24-07-2014
Taarifa za kipeperushi Taarifa za kipeperushi Kiromania 24-07-2014
Tabia za bidhaa Tabia za bidhaa Kiromania 24-07-2014
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiromania 24-07-2014
Taarifa za kipeperushi Taarifa za kipeperushi Kislovakia 24-07-2014
Tabia za bidhaa Tabia za bidhaa Kislovakia 24-07-2014
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kislovakia 24-07-2014
Taarifa za kipeperushi Taarifa za kipeperushi Kislovenia 24-07-2014
Tabia za bidhaa Tabia za bidhaa Kislovenia 24-07-2014
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kislovenia 24-07-2014
Taarifa za kipeperushi Taarifa za kipeperushi Kifinlandi 24-07-2014
Tabia za bidhaa Tabia za bidhaa Kifinlandi 24-07-2014
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kifinlandi 24-07-2014
Taarifa za kipeperushi Taarifa za kipeperushi Kiswidi 24-07-2014
Tabia za bidhaa Tabia za bidhaa Kiswidi 24-07-2014
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiswidi 24-07-2014
Taarifa za kipeperushi Taarifa za kipeperushi Kinorwe 24-07-2014
Tabia za bidhaa Tabia za bidhaa Kinorwe 24-07-2014
Taarifa za kipeperushi Taarifa za kipeperushi Kiaisilandi 24-07-2014
Tabia za bidhaa Tabia za bidhaa Kiaisilandi 24-07-2014
Taarifa za kipeperushi Taarifa za kipeperushi Kroeshia 24-07-2014
Tabia za bidhaa Tabia za bidhaa Kroeshia 24-07-2014
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kroeshia 24-07-2014

Tafuta arifu zinazohusiana na bidhaa hii

Taadhari Olanzapine Cipla

Olanzapine Cipla

Tazama historia ya hati

Historia ya nyaraka Historia ya nyaraka

Olanzapine Cipla (previously Olanzapine Neopharma)